Researchers find diabetes drugs harmful to women’s bone health
NEW YORK Two drugs for treating Type 2 diabetes could increase women’s risk of weak and easily broken bones, according to study published in the Canadian Medical Association Journal.
The drugs, GlaxoSmithKline’s Avandia (rosiglitazone) and Takeda’s Actos (pioglitazone), belong to a class of drugs called thiazolidinediones. Studies in the United States and United Kingdom already indicated that they increased fracture risks. In the latest study, the increased risk was found among women, but not among men.
The study examined data from 10 drug trials that used more than 13,000 patients. Among postmenopausal women with Type 2 diabetes, one-in-21 had a higher than average number of fractures.
FDA approves Galderma’s Epiduo Gel treatment for acne
ROCKVILLE, Md. The Food and Drug Administration has approved a new acne treatment by Galderma Laboratories, the agency announced Wednesday.
The treatment, Epiduo Gel, is known generically as adapalene and benzoyl peroxide and is used to treat acne vulgaris in patients aged 12 and older.
FDA records indicate the agency approved it Monday.
Galderma, based in Lausanne, Switzerland, had not made a statement about the approval at midday Wednesday.
Wyeth announces lay-offs at operations in Puerto Rico
SAN JUAN, Puerto Rico More than 200 Wyeth Pharmaceuticals employees in Puerto Rico will lose their jobs between the end of the year and February, according to the Associated Press.
The drug maker said it would lay off 276 workers as part of a restructuring plan and drop in demand. The company employs about 3,000 people in the territory.
A spokeswoman for the company said the availability of generics reduced demand for the anti-anxiety drug Effexor (venlafaxine hydrochloride) and the acid reflux disease drug Protonix (pantoprazole sodium).